Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 14 2024 - 8:30AM
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL;
NXLIW) today announced that it has commenced sales of its second
generation (Gen-2), 15 milliamp (mA) neurostimulation device into a
new mental health center in Oman, dedicated to the use of Nexalin’s
neurostimulation device for the treatment of patients with
substance abuse disorder (SUD).
Grand opening of mental health center dedicated to
Nexalin’s Gen-2 neurostimulation device
The new clinic opened and commenced treatment of
patients with Nexalin’s Gen-2 neurostimulation device following a
successful evaluation and inspection of the facility by the
Sultanate of Oman’s Ministry of Health, which ensures strict
quality standards and adherence to established and robust
guidelines and regulations. As previously announced, Nexalin was
recently granted regulatory approval for its Gen-2, 15 milliamp
(mA) neurostimulation device by the Sultanate of Oman’s Ministry of
Health.
Mark White, CEO of Nexalin Technology, stated,
“We are pleased to commence commercial sales of our Gen-2
neurostimulation device in Oman following regulatory approval by
the Sultanate of Oman’s Ministry of Health. Importantly, the new
center is exclusively focused on providing comprehensive treatment
of patients with SUD, utilizing Nexalin’s Gen-2 neurostimulation
device, with plans to expand into the treatment of other mental
health disorders. We believe the selection of Nexalin’s technology
as the cornerstone of a new health center is a significant
validation of our new and drug-free therapy in generating enhanced
patient therapeutic responses without adverse side effects.”
“I am extremely proud of the efforts by our
executives and staff, who supported the new health center's
leadership in obtaining Ministry of Health certification and
commissioning operations in record time. We believe this new health
center will serve as a model across the Middle East and around the
world as we work toward our goal of transforming the paradigm of
mental health treatment.”
“We are especially grateful for the support of
the National Committee for Narcotics and Psychotropics Substances
(NCNPS) and the officials who joined us for the opening ceremonies.
We appreciate their faith in our mission to combat addiction, as
well as the global mental health epidemic, while reducing the
growing dependence on pharmaceuticals that are often ineffective
and may have undesirable side effects.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative and
unique neurostimulation products to combat the ongoing global
mental health epidemic. Nexilin’s non-invasive products are
undetectable to the human body and are developed to provide relief
to those afflicted with mental health issues. Nexalin utilizes
bioelectronic medical technology to treat mental health issues.
Nexalin believes its neurostimulation medical devices can penetrate
structures deep in the mid-brain that are associated with mental
health disorders. Nexalin believes the deeper-penetrating waveform
in its next-generation devices will generate enhanced patient
response without any adverse side effects. The Nexalin Gen-2 15
milliamp (mA) neurostimulation device was recently approved in
China by the National Medical Products Administration (NMPA) for
the treatment of insomnia and depression. Additional
information about the Company is available at:
https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that
constitute "forward-looking statements," These statements relate to
future events or Nexalin’s future financial performance. Any
statements that refer to expectations, projections or other
characterizations of future events or circumstances or that are not
statements of historical fact (including without limitation
statements to the effect that Nexalin or its management “believes”,
“expects”, “anticipates”, “plans”, “intends” and similar
expressions) should be considered forward looking statements that
involve risks and uncertainties which could cause actual events or
Nexalin’s actual results to differ materially from those indicated
by the forward-looking statements. Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's Report on Form 10-K for the year
ended December 31, 2022 and other filings as filed with the
Securities and Exchange Commission. Copies of such filings are
available on the SEC's website, www.sec.gov. Such forward-looking
statements are made as of the date hereof and may become outdated
over time. Such forward-looking statements are made as of the date
hereof and may become outdated over time. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
Contact:Crescendo Communications, LLCTel: (212)
671-1020Email: NXL@crescendo-ir.com
- Grand opening of mental health center dedicated to Nexalin’s
Gen-2 neurostimulation device
Nexalin Technologies (NASDAQ:NXLIW)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nexalin Technologies (NASDAQ:NXLIW)
Historical Stock Chart
From Aug 2023 to Aug 2024